Mirum Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Feb 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 25, 2026
MIRM$93.33-1.4%Stored close · as of Nov 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
Checking your notes…
| Common Stock · AdditionalPaid-InCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveIncome (Loss) · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of December 31, 2022 | 36,956,345 | $4 | $535,074 | $(392,824) | $(217) | $142,037 |
| Issuance of common stock in private placement, net of issuance costs of $7,796 | 8,000,000 | 1 | 202,203 | — | — | 202,204 |
| Issuance of common stock in at-the-market offerings, net of issuance costs of $518 | 658,206 | — | 14,480 | — | — | 14,480 |
| Issuance of common stock in connection with asset acquisition | 231,624 | — | 5,188 | — | — | 5,188 |
| Issuance of common stock in connection with equity award plans | 760,226 | — | 8,279 | — | — | 8,279 |
| Issuance of common stock in connection with employee stock purchase plan | 116,742 | — | 2,191 | — | — | 2,191 |
| Stock-based compensation | — | — | 35,845 | — | — | 35,845 |
| Net loss | — | — | — | (163,415) | — | (163,415) |
| Other comprehensive income | — | — | — | — | 1,861 | 1,861 |
| Balance as of December 31, 2023 | 46,723,143 | $5 | $803,260 | $(556,239) | $1,644 | $248,670 |
| Issuance of common stock in connection with equity award plans | 1,489,510 | — | 15,059 | — | — | 15,059 |
| Issuance of common stock in connection with employee stock purchase plan | 125,443 | — | 2,640 | — | — | 2,640 |
| Stock-based compensation | — | — | 49,230 | — | — | 49,230 |
| Net loss | — | — | — | (87,942) | — | (87,942) |
| Other comprehensive loss | — | — | — | — | (2,017) | (2,017) |
| Balance as of December 31, 2024 | 48,338,096 | $5 | $870,189 | $(644,181) | $(373) | $225,640 |
| Issuance of common stock in connection with equity award plans | 3,450,566 | — | 36,200 | — | — | 36,200 |
| Issuance of common stock in connection with employee stock purchase plan | 106,977 | 3,942 | 3,942 | |||
| Conversion of convertible notes, net | 752 | — | 24 | — | — | 24 |
| Stock-based compensation | — | — | 71,523 | — | — | 71,523 |
| Net loss | — | — | — | (23,363) | — | (23,363) |
| Other comprehensive income | — | — | — | — | 724 | 724 |
| Balance as of December 31, 2025 | 51,896,391 | $5 | $981,878 | $(667,544) | $351 | $314,690 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.